

Enantioselective Synthesis of
(–)-LL-C10037 α from Benzoquinone


Sean T. Murphy, Josef R. Bencsik, and Carl R. Johnson*

Department of Chemistry, Wayne State University, Detroit, Michigan 48202

crj@chem.wayne.edu

Received September 13, 1999


ABSTRACT



The enantioselective total synthesis of the *Streptomyces* metabolite (–)-LL-C10037 α has been accomplished in 10 steps and 20% overall yield. An early chiral intermediate was resolved with *Candida rugosa* lipase to provide (+)-5 with an enantiomeric excess $\geq 98\%$. The synthesis is notable in that no protecting groups are required and that all carbons in the core structure of LL-C10037 α are derived from the readily available *p*-benzoquinone.

LL-C10037 α (**1**) is a metabolite of *Streptomyces* LL-C10037 and shows antibacterial and antitumor activity.¹ After the initial report of the isolation,¹ the structure was revised and shown by an X-ray diffraction study to be the epoxyquinol **1**.² The absolute configuration was later confirmed by X-ray analysis of an ester derivative.³ The epoxyquinol core of LL-C10037 α is found in a number of other antibiotics including the manumycins,⁴ such as manumycin A (**2**), alisamycin,⁵ asukamycin,⁶ and nisamycin.⁷ The manumycins are note-

worthy because they are also potent and selective inhibitors of Ras farnesyltransferase,⁸ an enzyme linked to many human cancers.



Racemic syntheses of LL-C10037 α have been published by the groups of both Wipf⁹ and Taylor.¹⁰ One enantiose-

(1) Lee, M. D.; Fantini, A. A.; Morton, G. O.; James, J. C.; Borders, D. B.; Testa, R. T. *J. Antibiot.* **1984**, *37*, 1149–1152.

(2) Whittle, Y. G.; Gould, S. J. *J. Am. Chem. Soc.* **1987**, *109*, 5043–5044.

(3) Shen, B.; Whittle, Y. G.; Gould, S. J.; Keszler, D. A. *J. Org. Chem.* **1990**, *55*, 4422–4426.

(4) (a) Buzzetti, F.; Gümman, E.; Hütter, R.; Keller-Schierlein, W.; Neipp, L.; Prelog, V.; Zähner, H. *Pharm. Acta Helv.* **1963**, *38*, 871. (b) Schröder, K.; Zeeck, A. *Tetrahedron Lett.* **1973**, 4995. (c) Zeeck, A.; Schröder, K.; Frobel, K.; Grote, R.; Thiericke, R. *J. Antibiot.* **1987**, *40*, 1530. (d) Zeeck, A.; Frobel, K.; Heusel, C.; Schröder, K.; Thiericke, R. *J. Antibiot.* **1987**, *40*, 1541. (e) Thiericke, R.; Stellwaag, M.; Zeeck, A.; Snatzke, G. *J. Antibiot.* **1987**, *40*, 1549. (f) Thiericke, R.; Zeeck, A.; Nakagawa, A.; Omura, S.; Herrold, R. E.; Wu, S. T. S.; Beale, J. M.; Floss, H. G. *J. Am. Chem. Soc.* **1990**, *112*, 3979. (g) Sattler, I.; Gröne, C.; Zeeck, A. *J. Org. Chem.* **1993**, *58*, 6583. (h) Shu, Y.-Z.; Huang, S.; Wang, R. R.; Lam, K. S.; Klohr, S. E.; Volk, K. J.; Pirnik, D. M.; Wells, J. S.; Fernandes, P. B.; Patel, P. S. *J. Antibiot.* **1994**, *47*, 324.


(5) (a) Franco, C. M. M.; Maurya, R.; Vijayakumar, E. K. S.; Chatterjee, S.; Blumbach, J.; Ganguli, B. N. *J. Antibiot.* **1991**, *44*, 1289. (b) Chatterjee, S.; Vijayakumar, E. K. S.; Franco, C. M. M.; Blumbach, J.; Ganguli, B. N. *J. Antibiot.* **1993**, *46*, 1027. (c) Hayashi, K.; Nakagawa, M.; Fujita, T.; Nakayama, M. *Biosci. Biotech. Biochem.* **1994**, *58*, 1332.

(6) (a) Omura, S.; Kitao, C.; Tanaka, H.; Oiwa, R.; Takahashi, Y.; Nakagawa, A.; Shimada, M.; Iwai, Y. *J. Antibiot.* **1976**, *29*, 876. (b) Kakinuma, K.; Ikekawa, N.; Nakagawa, A.; Omura, S. *J. Am. Chem. Soc.* **1979**, *101*, 3402. (c) Cho, H. G.; Sattler, I.; Beale, J. M.; Zeeck, A.; Floss, H. G. *J. Org. Chem.* **1993**, *58*, 7925.

(7) (a) Hayashi, K.; Nakagawa, M.; Fujita, T.; Tanimori, S.; Nakayama, M. *J. Antibiot.* **1993**, *46*, 1904. (b) Hayashi, K.; Nakagawa, M.; Nakayama, M. *J. Antibiot.* **1994**, *47*, 1104. (c) Hayashi, K.; Nakagawa, M.; Fujita, T.; Tanimori, S.; Nakayama, M. *J. Antibiot.* **1994**, *47*, 1110.

lective synthesis has also been accomplished, published by Wipf et al. in 1995.^{9b} The synthesis relied on a chiral auxiliary to achieve enantioselectivity in an epoxidation reaction and was completed in an overall yield of ca. 1% from 2,5-dimethoxyaniline. Curiously, the enantiomer of (–)-LL-C10037 α is also a natural product. The (+)-enantiomer, named (+)-MT 35214, has been efficiently synthesized by Taylor et al. using a phase-transfer catalyst to effect an enantioselective epoxidation. Unfortunately, a catalyst could not be found to produce the enantiomeric epoxide, thus precluding a synthesis of (–)-LL-C10037 α .

Continuing our program of using enzymes in the enantioselective synthesis of highly functionalized, biologically active molecules,¹¹ we now report the synthesis of LL-C10037 α starting from readily available benzoquinone (Scheme 1). The first part of the synthesis follows previous



^a Reagents: (a) Br₂, 0 °C; (b) NaBH₄, 0 °C, 81% over two steps (ref 13); (c) KOH, 0 °C, 92%; (d) (±)-5 (6.8 g), *Candida rugosa* lipase (Sigma) (200 wt %), 4:1 toluene/isopropenyl acetate (125 mL), 6 d, 47%, ≥98% ee; (e) NaN₃, ZnSO₄, 95%; (f) MCPBA, 94%; (g) KOH, 0 °C, 86%; (h) Pd/S, H₂; (i) Ac₂O, Et₃N, 84% over two steps; (j) Dess–Martin periodinane, 87%.


work by our group in which epoxide **5** was enzymatically resolved and shown to react with various nucleophiles by opening the epoxide at the allylic position.¹² Following the literature procedure from Altenbach, Stegelmeier, and Vogel,¹³ *p*-benzoquinone was sequentially trans-brominated and stereoselectively reduced with sodium borohydride to give

the diol **4**. By treating the C₂-symmetrical diol **4** with base and maintaining the temperature at 0 °C, only one of the hydroxyl groups closes to form the monoepoxide (±)-**5** in excellent yield (92%). Maintaining the temperature at 0 °C is crucial during this step, since permitting the reaction to warm to room temperature allows for formation of the corresponding diepoxide.¹³

Racemic epoxide **5** was exposed to *Candida rugosa* lipase in toluene/isopropenyl acetate; only (–)-**5** was acetylated, leaving (+)-**5** untouched. Separation from the acetylated product by flash chromatography produced (+)-**5** in 47% yield and ≥98% ee [[α]_D²⁵ +170 (c 1.0, CHCl₃) (lit.¹² [α]_D²⁵ +174 (c 1.0, CHCl₃); lit.¹⁴ [α]_D²⁵ +170.6 (c 0.812, CHCl₃)]. Recrystallization did not result in increased optical rotation.

To introduce the nitrogen present in the natural product, (+)-**5** was treated with sodium azide in the presence of zinc sulfate to form azide (–)-**6** in 95% yield. As expected, the epoxide was attacked at the more labile allylic position (confirmed by X-ray analysis of (±)-**6**). Next, the oxygen that was to become the hydroxyl group in the final product was introduced stereoselectively by hydroxyl-directed *m*-CPBA epoxidation¹⁵ to give (–)-**7** (94%). The relative stereochemistry of the epoxidation was confirmed by X-ray analysis on (±)-**7**. The epoxide (–)-**7** was transformed into the diepoxide (–)-**8** with potassium hydroxide in methanol at 0 °C (86%).

We anticipated a tandem oxidation/β-elimination reaction on amide **10** would lead directly to the final product **1**. To arrive at **10**, we required chemoselective reduction of the azide function in (–)-**8**, leading to **9**. Our initial attempts to reduce the azide by hydrogenation¹⁶ produced the desired amine **9** along with an epoxide-reduced product tentatively assigned structure **12** (Scheme 2). A variety of catalysts were



examined, including palladium on carbon, palladium hydroxide on carbon (Pearlman's catalyst), and palladium, sulfided, 5 wt % on carbon (Aldrich) as well as a number of

(8) (a) Hara, M.; Akasaka, K.; Akinaga, S.; Okabe, M.; Nakano, H.; Gomez, R.; Wood, D.; Uh, M.; Tamanoi, F. *Proc. Natl. Acad. Sci. U.S.A.* **1993**, *90*, 2281. (b) Nagase, T.; Kawata, S.; Yamazaki, E.; Ishiguro, H.; Matuzawa, Y. *Hepatology* **1993**, *18*, 190. (c) Hara, M.; Han, M. *Proc. Natl. Acad. Sci. U.S.A.* **1995**, *92*, 3333.

solvents (EtOH, MeOH, EtOAc); all produced mixtures. In examining other methods of azide reduction, we found that reduction with triphenylphosphine¹⁷ proceeded smoothly to give the desired product **9**. Unfortunately, the triphenylphosphine oxide produced in the reaction made purification of **9** or the diacetylated product **13** extremely difficult. Finally, in examining the Pd hydrogenation conditions further, we found that the sulfided palladium on carbon catalyst when run in THF gave the amine **9** as the only detectable product by TLC and NMR. Due to the extreme polarity of the amine **9**, the crude material was acetylated directly with acetic anhydride and triethylamine to provide the penultimate acetamide **10** (84% over two steps).

A potential complication in the strategy of an oxidation/elimination sequence for conversion of **10** to **1** is that the elimination reveals a new alcohol in the desired product **1** that could be further oxidized to an epoxyquinone. To our delight, the Dess–Martin periodinane¹⁸ reacted quickly with **10** in acetonitrile to provide (–)-LL-C10037α in a very good

yield of 87%. The reaction appeared to be complete within 20 min, and no signs of the ketone **11** were seen by TLC. To account for the selective formation of **1**, we propose that the periodinane reacts quickly with the hydroxyl functionality, thus forming a complex and thereby sequestering all of the reagent so that as the product **1** forms no reagent is available for over-oxidation to an epoxyquinone. The proton and carbon NMR spectra of the synthesized (–)-**1** matched perfectly those of the natural product.^{1,2} After one recrystallization, the optical rotation and melting point were in excellent agreement with the naturally obtained material: mp 149–151 °C; $[\alpha]^{22}_{\text{D}} -201$ (*c* 0.34, MeOH) [lit.¹ mp 153 °C; lit.³ $[\alpha]^{20}_{\text{D}} -202$ (*c* 0.334, MeOH)].

In summary, we have synthesized (–)-LL-C10037α using an enzymatic resolution on an early intermediate. Starting from benzoquinone, the title compound was synthesized in 10 steps and 20% overall yield.¹⁹ Notable reactions include a chemoselective azide reduction with sulfided palladium on carbon and a tandem oxidation/β-elimination reaction. Although LL-C10037α is a densely functionalized small molecule, no protecting groups were needed during the synthesis, which contributed to the high efficiency achieved.

Acknowledgment. We gratefully acknowledge support of the National Science Foundation (CHE-9801679). We thank Dr. Mary Jane Heeg for the X-ray structure determinations and Dr. Lew Hryhorczuk for assistance with mass spectroscopy analyses.

Supporting Information Available: Experimental procedures and full characterization for the optically active compounds **6–10** and (–)-**1**, ¹H NMR spectra for these compounds, and X-ray structures for (±)-**6** and (±)-**7**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL991038N

- (9) (a) Wipf, P.; Kim, Y. *J. Org. Chem.* **1994**, *59*, 3518–3519. (b) Wipf, P.; Kim, Y.; Jahn, H. *Synthesis* **1995**, 1549–1561.
- (10) (a) Kapfer, I.; Lewis, N. J.; Macdonald, G.; Taylor, R. J. K. *Tetrahedron Lett.* **1996**, *37*, 2101–2104. (b) Taylor, R. J. K.; Alcaraz, L.; Kapfer-Eyer, I.; Macdonald, G.; Wei, X.; Lewis, N. *Synthesis* **1998**, 775–790.
- (11) (a) Johnson, C. R. *Acc. Chem. Res.* **1998**, *31*, 333–341. (b) Johnson, C. R.; Wells, G. W. *Curr. Opinion Chem. Biol.* **1998**, *2*, 70–76.
- (12) Kohrt, J. T.; Gu, J.-X.; Johnson, C. R. *J. Org. Chem.* **1998**, *63*, 5088–5093.
- (13) Altenbach, H.-J.; Stegelmeier, H.; Vogel, E. *Tetrahedron Lett.* **1978**, 3333–3336.
- (14) Koreeda, M.; Yoshihara, M. *J. Chem. Soc., Chem. Commun.* **1981**, 974–976.
- (15) Henbest, H. B.; Wilson, R. A. L. *J. Chem. Soc.* **1959**, 1958–1965.
- (16) For a review on the chemistry of azides, including reduction, see: Scriven, E. F. V.; Turnbull, K. *Chem. Rev.* **1988**, *88*, 297–368.
- (17) Vaultier, M.; Knouzi, N.; Carrie, R. *Tetrahedron Lett.* **1983**, *24*, 763.
- (18) (a) Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4156–4158. (b) Dess, D. B.; Martin, J. C. *J. Am. Chem. Soc.* **1991**, *113*, 7277–7287.
- (19) The overall yield includes the resolution step, which has a maximum yield of only 50%.